Evidence map›Paper›PMID 10430860›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1999

Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens.

J S Smith, J R Keller, N C Lohrey, C S McCauslin, M Ortiz, K Cowan, S E Spence

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2004
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Metabolic biotinylation of recombinant proteins in mammalian cells and in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2000
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

J S SmithLaboratories of Molecular Immunoregulation, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702, USA.
J R Keller
N C Lohrey
C S McCauslin
M Ortiz
K Cowan
S E Spence
Science Applications International Corporation (United States) · USNational Cancer Institute · US

Funding

OPERATIONS &TECHNICAL SUPPORTN01CO056000 · CO · SCIENCE APPLICATIONS INTERNATIONAL CORP · PI FISCHINGER, PETER J · 1995 to 2000
$95.0M
Regulation of Hematopoiesis: Gene Therapy PotentialZ01BC010001 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLER, JONATHAN R · 1996 to 2008
$2.1M
NCI NIH HHS N01-CO-56000
6 · The paper itself

Abstract

The inability of adenovirus to infect primitive hematopoietic cells presents an obstacle to the use of adenovirus vectors for gene transfer to these cell types. Therefore, expanding the tropism of adenovirus vectors to unique cell surface antigens would be an important development for gene therapy protocols. In this study, we sought to redirect infection of adenovirus vectors to primitive human hematopoietic cells that universally express the c-Kit receptor on their cell surface. To accomplish this, a vector was constructed by covalently linking biotin molecules to recombinant adenovirus, followed by addition of the biotinylated ligand for the c-Kit receptor, stem cell factor (SCF), through an avidin bridge. Gene transfer was directed specifically to c-Kit-positive hematopoietic cell lines, resulting in up to a 2,440-fold increase in luciferase expression with frequencies equivalent to recombinant virus infection of permissive cells. Substitution of biotinylated antibodies directed against c-Kit, CD34 (binds L-selectin), and CD44 (hyaluronate receptor) receptors for biotinylated SCF resulted in 50-, 8-, and 260-fold increases in reporter gene expression, respectively, demonstrating that infection also could be redirected through antibody-antigen interactions and through antigens other than growth factor receptors. The versatility of this vector was demonstrated further by infection of primary T cells with vectors targeted with antibodies to CD44 (resting and activated T cells) and biotinylated IL-2 (activated T cells only). Taken together, directly biotinylated adenovirus vectors represent a versatile and efficient method for redirection of virus infection to specific cells.

Indexed as

Genetic VectorsAdenoviruses, HumanAntibodies, MonoclonalAntigens, CDAntigens, CD34BiotinylationCell LineCells, CulturedCytomegalovirusGreen Fluorescent ProteinsHumansHyaluronan ReceptorsLuminescent ProteinsProto-Oncogene Proteins c-kitRecombinant Fusion ProteinsRecombination, GeneticAntibodies, MonoclonalAntigens, CDAntigens, CD34Green Fluorescent ProteinsHyaluronan ReceptorsLuminescent ProteinsProto-Oncogene Proteins c-kitRecombinant Fusion ProteinsStem Cell Factor

Identifiers

PMID10430860
PMCPMC17697
OpenAlexW2148494593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.